Stock Analysis

NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)

NasdaqCM:NAOV
Source: Shutterstock

NanoVibronix (NASDAQ:NAOV) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$376.0k (down 18% from 3Q 2023).
  • Net loss: US$998.0k (loss widened by 37% from 3Q 2023).
  • US$0.36 loss per share.
earnings-and-revenue-history
NasdaqCM:NAOV Earnings and Revenue History November 17th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

NanoVibronix shares are down 1.5% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with NanoVibronix (at least 3 which are significant), and understanding them should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if NanoVibronix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqCM:NAOV

NanoVibronix

Through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally.

Moderate with adequate balance sheet.